NCT03246555已完成3 期
A Randomized, Double-blind, Active-controlled, 2-parallel Group, Optional Titration, Multicenter, Phase 3b Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without Diuretics Combination in Elderly Patients With Essential Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 241
- 试验地点
- 1
- 主要终点
- Change in siSBP
研究概览
简要总结
The objective of this study is to confirm the noninferiority of the blood pressure lowering effect of fimasartan and evaluate its safety compared to perindopril in the elderly with essential hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily provided a written consent to participate in this clinical study after receiving an explanation of this study
- •Elderly aged 70 years or older
- •At the screening visit (Visit 1), Blood pressure: Mean blood pressure measured 3 times on the selected arm is as below.
- •For treatment-naïve patients who have not taken drugs for hypertension within the last 3 months from the screening visit: Mean siSBP ≥ 140mmHg
- •For patients with essential hypertension who are taking drugs for hypertension: Mean siSBP ≥ 130mmHg
- •At the baseline visit (Visit 2), Blood pressure: Patients with mild to moderate essential hypertension whose mean siSBP measured 3 times on the selected arm is ≥140 mmHg Patients with treatment compliance of ≥70% during the placebo run-in period
- •Capable of understanding written instructions, cooperative, able to participate until the end of the clinical study
排除标准
- •Severe hypertension patients with mean siSBP ≥ 180 mmHg or siDBP ≥ 110 mmHg (office BP) at the screening visit (Visit 1) and the baseline visit (Visit 2) (However, at screening, it is based on the blood pressures measured from both arms, and the patient is excluded if the result from any of the arms falls within the criteria.)
- •Patients with siSBP ≥ 20 mmHg and siDBP ≥ 10 mmHg in the difference between blood pressures in the selected arm at the screening visit (Visit 1)
- •Patients with a history of secondary hypertension and any history suspected of secondary hypertension (but not limited to the following: coarctation of the aorta, primary hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc.)
- •Orthostatic hypotension with symptoms
- •Patients with insulin-dependent diabetes mellitus or uncontrolled diabetes mellitus (HbA1c > 9.0% at the screening visit (Visit 1))
- •Patients with a history of malignant tumor, including leukemia and lymphoma, within the past 5 years (however, participation is allowed if it has not recurred for at least 5 years after a tumor surgery)
- •Patients with any chronic inflammatory disease requiring chronic anti-inflammatory treatment, consumption disease, autoimmune disease like rheumatoid arthritis and systemic lupus erythematosus, etc., or connective tissue disease at present or in the past
- •Patients with a history of hypersensitivity reaction to any component of the investigational product and its similar compound Renin-angiotensin system inhibitors, ACE inhibitors, thiazide diuretics and sulfonamides, Yellow 5 (Sunset Yellow FCF), etc.
- •Patients with hyperlipidemia undergoing LDL (low density lipoprotein) apheresis (patients undergoing LDL hemapheresis using a dextran sulfate cellulose)
研究组 & 干预措施
Fimasartan or Fimasartan/Hydrochlorothiazide
Experimental
干预措施: Fimasartan or Fimasartan/Hydrochlorothiazide (Drug)
Perindopril or Perindopril/Indapamide
Active Comparator
干预措施: Perindopril or Perindopril/Indapamide (Drug)
结局指标
主要结局
Change in siSBP
时间窗: 8 weeks
Change in siSBP from baseline after the administration of the investigational product for 8 weeks
次要结局
- Change in siSBP(Weeks 4, 16 and 24)
- Change in siDBP(Weeks 4, 8, 16 and 24)
- Blood pressure response rate(4, 8 and 16 weeks)
- Change from baseline in the differences in standing SBP and DBP compared to their sitting measurements(4, 8, 16 and 24 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)HypertensionNCT00092209Organon and Co840
已完成
3 期
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.Essential HypertensionNCT00343551Novartis654
已完成
3 期
Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential HypertensionEssential HypertensionNCT01237223Novartis1,342
已完成
2 期
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood PressureHypertensionNCT00422461Pfizer135
已完成
3 期
Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential HypertensionBlood Pressure, HighHypertensionNCT00355589Pfizer